(Reuters) - The Food and Drug Administration staff, however, said they would ask an advisory panel that meets Tuesday for advice "regarding the possible need for special labeling as well as whether additional clinical trials should be performed to address particular safety issues."
Maraviroc fights HIV differently from older medicines. It blocks the CCR5 co-receptor that serves as a main entry point for the virus into cells.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment